Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated reports developments for a global medical technology business that supplies hospitals and healthcare providers with devices used in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Its established brands include Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Recurring Teleflex news covers quarterly financial results, outlook updates, revenue trends by global product category, portfolio realignment and integration of acquired vascular intervention assets. Company updates also include governance and leadership changes, board committee matters, capital allocation actions, shareholder communications and operational initiatives such as integrated demand and supply planning.
Teleflex has released a survey indicating that men with urinary symptoms due to benign prostatic hyperplasia (BPH) often engage in extreme bathroom planning, impacting their daily activities. Conducted with 1,000 U.S. men aged 45+, the study found that 45.49% avoided enjoyable events due to urinary issues. Over 70% reported diminished energy levels from nighttime awakenings. While many men (66.81%) are interested in minimally invasive procedures, nearly 25% find current BPH medications ineffective. The UroLift System offers a promising alternative for symptom relief.
Teleflex's Executive Vice President and CFO, Thomas Powell, will present at the Raymond James 2021 Human Health Innovation Conference on June 21, 2021, at 8:40 a.m. (ET). A live audio webcast and slide presentation will be available on the Teleflex website.
Teleflex offers a range of medical technologies aimed at improving health and quality of life. Their innovative solutions cover areas such as vascular access, interventional cardiology, anesthesia, and more. The company, listed on the NYSE as TFX, is dedicated to addressing unmet clinical needs.
Teleflex has announced a definitive agreement to sell a significant portion of its Respiratory business to Medline Industries for $286 million, minus $12 million in working capital. The divested product lines generated $139 million in revenue in 2020, with flat growth expected in 2021. The transaction, anticipated to close in early Q3 2021, will incur a revenue headwind of $28-32 million and dilute adjusted earnings per share by $0.10-$0.15. Teleflex plans to use the proceeds to reduce debt and focus on core market segments.
Thomas Powell, Executive Vice President and CFO of Teleflex (NYSE: TFX), will present at the UBS Global Healthcare Virtual Conference on May 25, 2021, at 3:00 p.m. (ET). The event will include a live audio webcast and a slide presentation available on the investor section of the Teleflex website. Teleflex is known for its innovative medical technologies aimed at improving health outcomes across various fields, including vascular access and emergency medicine. The company emphasizes its commitment to addressing unmet clinical needs through its diverse product portfolio.
Teleflex Incorporated (NYSE: TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 15, 2021, to shareholders of record as of May 14, 2021. This decision reflects the company's commitment to returning value to its shareholders while continuing to focus on improving healthcare through innovative medical technologies across various fields including vascular access and anesthesia. Teleflex maintains a diverse portfolio aimed at meeting unmet clinical needs.
Teleflex announced its Q1 2021 results, reporting revenues of $633.9 million, a modest increase of 0.5% year-over-year. However, on a constant currency basis, revenues fell by 2.6%. The GAAP diluted EPS dropped 43.2% to $1.58, while adjusted diluted EPS rose by 5.5% to $2.87. The company raised its full-year revenue growth guidance but lowered its GAAP diluted EPS forecast. A restructuring plan is in place, expected to yield annual savings of $13 million to $16 million.
Teleflex (NYSE: TFX) announced that Liam Kelly, Chairman, President, and CEO, will speak at the Bank of America Securities 2021 Virtual Health Care Conference on May 11, 2021, at 8:00 a.m. (ET). A live audio webcast and presentation slides will be accessible on the investor section of the Teleflex website.
Teleflex is dedicated to medical technologies that enhance health and quality of life, with a diverse portfolio in areas like vascular access and emergency medicine. More information can be found at teleflex.com.
Teleflex Incorporated (NYSE: TFX) will announce its first quarter 2021 financial results before the market opens on April 29, 2021. An investor conference call is scheduled for 8:00 a.m. (ET) on the same day, accessible via a live audio webcast. A replay will be available from 11:00 a.m. on April 29 until May 6, 2021. Teleflex provides medical technologies aimed at improving patient health, focusing on innovation in various medical fields.
Teleflex is set to participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 24, 2021, at 9:15 AM (ET). Jake Elguicze, Treasurer and Vice President of Investor Relations, will present at the event. Investors can access a live audio webcast and slides on the company's website. Teleflex specializes in medical technologies aimed at improving health outcomes across various fields, including vascular access and anesthesia. For additional details, visit www.teleflex.com.
Teleflex announced that over 250,000 patients worldwide have been treated with the UroLift® System, a minimally invasive procedure for benign prostatic hyperplasia (BPH). In the U.S., BPH affects more than 42 million men, with about 12 million receiving treatment. The UroLift System differs from traditional options by providing rapid recovery and maintaining sexual function. Recent data reveal improved patient experiences with lower catheterization rates and higher satisfaction levels. The UroLift System has become a standard of care in urology practices, underscoring its effectiveness.